{"nctId":"NCT01289119","briefTitle":"Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes","startDateStruct":{"date":"2010-12"},"conditions":["Diabetes Mellitus, Type 2"],"count":506,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo to alogliptin"]},{"label":"Alogliptin Monotherapy","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin"]},{"label":"Metformin","type":"OTHER","interventionNames":["Drug: Placebo to alogliptin","Drug: Metformin"]},{"label":"Metformin + Alogliptin Add-on Therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin","Drug: Metformin"]},{"label":"Pioglitazone","type":"OTHER","interventionNames":["Drug: Placebo to alogliptin","Drug: Pioglitazone"]},{"label":"Pioglitazone + Alogliptin Add-on Therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Alogliptin","Drug: Pioglitazone"]}],"interventions":[{"name":"Alogliptin","otherNames":["SYR-322"]},{"name":"Placebo to alogliptin","otherNames":[]},{"name":"Metformin","otherNames":["Fortamet","Glucophage","Glumetza"]},{"name":"Pioglitazone","otherNames":["Actos"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a historical diagnosis of Type 2 Diabetes Mellitus.\n* Has a body mass index between acceptable range.\n* Is experiencing inadequate glycemic control.\n* Body weight keeps constant.\n* Females of childbearing potential and males who are sexually active agree to use routinely adequate contraception from signing of informed consent throughout the duration of the study and for 30 days after last dose.\n\nExclusion Criteria:\n\n* Has participated in another clinical study within the past 90 days or has received any investigational compound within 30 days prior to randomization.\n* Has a systolic blood pressure beyond the acceptable range at Screening visit.\n* Has New York Heart Association Class III or IV heart failure regardless of therapy.\n* Has any major illness or debility that in the investigator's opinion prohibits the subject from completing the study.\n* Has a history of hypersensitivity or allergies to any DPP-4 inhibitor.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Glycosylated Hemoglobin (HbA1c)","description":"The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at Week 16. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.42","spread":"0.074"},{"groupId":"OG001","value":"-0.99","spread":"0.074"},{"groupId":"OG002","value":"-0.22","spread":"0.065"},{"groupId":"OG003","value":"-0.91","spread":"0.065"},{"groupId":"OG004","value":"-0.25","spread":"0.097"},{"groupId":"OG005","value":"-0.76","spread":"0.101"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c Over Time","description":"The change from Baseline in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) at Weeks 4, 8 and 12. Least squares means are derived from an analysis of covariance (ANCOVA) model with treatment as a fixed effect, and baseline HbA1c as a covariate for the monotherapy, baseline HbA1c with baseline metformin dose as covariates for the metformin therapy, baseline HbA1c with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.24","spread":"0.059"},{"groupId":"OG001","value":"-0.56","spread":"0.059"},{"groupId":"OG002","value":"-0.15","spread":"0.036"},{"groupId":"OG003","value":"-0.43","spread":"0.036"},{"groupId":"OG004","value":"-0.09","spread":"0.064"},{"groupId":"OG005","value":"-0.44","spread":"0.066"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.39","spread":"0.068"},{"groupId":"OG001","value":"-0.86","spread":"0.068"},{"groupId":"OG002","value":"-0.15","spread":"0.057"},{"groupId":"OG003","value":"-0.66","spread":"0.057"},{"groupId":"OG004","value":"-0.31","spread":"0.094"},{"groupId":"OG005","value":"-0.70","spread":"0.098"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"0.078"},{"groupId":"OG001","value":"-0.99","spread":"0.078"},{"groupId":"OG002","value":"-0.24","spread":"0.069"},{"groupId":"OG003","value":"-0.86","spread":"0.068"},{"groupId":"OG004","value":"-0.25","spread":"0.102"},{"groupId":"OG005","value":"-0.77","spread":"0.106"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose Over Time","description":"The change from Baseline in fasting plasma glucose (FPG) at Weeks 4, 8, 12 and 16. Least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline FPG as a covariate for the monotherapy, baseline FPG with baseline metformin dose as covariates for the metformin therapy, baseline FPG with baseline metformin therapy status and baseline pioglitazone dose as covariates for the pioglitazone therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.331","spread":"0.1221"},{"groupId":"OG001","value":"-0.719","spread":"0.1235"},{"groupId":"OG002","value":"-0.251","spread":"0.1454"},{"groupId":"OG003","value":"-0.985","spread":"0.1454"},{"groupId":"OG004","value":"0.284","spread":"0.2505"},{"groupId":"OG005","value":"-0.985","spread":"0.2603"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.330","spread":"0.1224"},{"groupId":"OG001","value":"-1.015","spread":"0.1224"},{"groupId":"OG002","value":"-0.235","spread":"0.1397"},{"groupId":"OG003","value":"-1.265","spread":"0.1397"},{"groupId":"OG004","value":"-0.038","spread":"0.2503"},{"groupId":"OG005","value":"-0.924","spread":"0.2600"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.411","spread":"0.1515"},{"groupId":"OG001","value":"-1.123","spread":"0.1515"},{"groupId":"OG002","value":"-0.335","spread":"0.1600"},{"groupId":"OG003","value":"-1.270","spread":"0.1600"},{"groupId":"OG004","value":"-0.187","spread":"0.2484"},{"groupId":"OG005","value":"-1.177","spread":"0.2581"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.317","spread":"0.1556"},{"groupId":"OG001","value":"-1.243","spread":"0.1556"},{"groupId":"OG002","value":"-0.512","spread":"0.1565"},{"groupId":"OG003","value":"-1.240","spread":"0.1565"},{"groupId":"OG004","value":"-0.114","spread":"0.2579"},{"groupId":"OG005","value":"-1.070","spread":"0.2679"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Marked Hyperglycemia","description":"Marked Hyperglycemia was defined as fasting plasma glucose greater than or equal to 200 mg/dL (11.1 mmol/L).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.9","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"25.8","spread":null},{"groupId":"OG003","value":"13.4","spread":null},{"groupId":"OG004","value":"23.8","spread":null},{"groupId":"OG005","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"The change between body weight measured at Baseline and body weight measured at Weeks 8 and 16. The least squares means are derived from an ANCOVA model with treatment as a fixed effect, and baseline body weight as a covariate for the monotherapy, baseline body weight with baseline metformin dose as covariates for the add-on to metformin therapy, baseline body weight with baseline metformin therapy status and baseline pioglitazone dose as covariates for the add-on to pioglitazone therapy.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.04","spread":"0.210"},{"groupId":"OG001","value":"-0.71","spread":"0.211"},{"groupId":"OG002","value":"-0.82","spread":"0.170"},{"groupId":"OG003","value":"-0.43","spread":"0.168"},{"groupId":"OG004","value":"-0.74","spread":"0.286"},{"groupId":"OG005","value":"-0.15","spread":"0.304"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.55","spread":"0.244"},{"groupId":"OG001","value":"-0.89","spread":"0.245"},{"groupId":"OG002","value":"-1.06","spread":"0.219"},{"groupId":"OG003","value":"-0.76","spread":"0.217"},{"groupId":"OG004","value":"-0.68","spread":"0.364"},{"groupId":"OG005","value":"-0.10","spread":"0.388"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c ≤6.5% at Week 16","description":"Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 6.5% at Week 16.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","spread":null},{"groupId":"OG001","value":"36.7","spread":null},{"groupId":"OG002","value":"4.1","spread":null},{"groupId":"OG003","value":"21.4","spread":null},{"groupId":"OG004","value":"9.5","spread":null},{"groupId":"OG005","value":"30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c ≤7.0% at Week 16","description":"Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.0% at Week 16.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.0","spread":null},{"groupId":"OG001","value":"63.3","spread":null},{"groupId":"OG002","value":"25.8","spread":null},{"groupId":"OG003","value":"55.1","spread":null},{"groupId":"OG004","value":"31.7","spread":null},{"groupId":"OG005","value":"61.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c ≤7.5% at Week 16","description":"Clinical response was assessed by the percentage of participants with HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) less than or equal to 7.5% at Week 16.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.3","spread":null},{"groupId":"OG001","value":"81.1","spread":null},{"groupId":"OG002","value":"50.5","spread":null},{"groupId":"OG003","value":"80.6","spread":null},{"groupId":"OG004","value":"47.6","spread":null},{"groupId":"OG005","value":"85.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Decrease in HbA1c ≥ 0.5%","description":"Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 0.5% at Week 16.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"84.4","spread":null},{"groupId":"OG002","value":"37.1","spread":null},{"groupId":"OG003","value":"70.4","spread":null},{"groupId":"OG004","value":"42.9","spread":null},{"groupId":"OG005","value":"76.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Decrease in HbA1c ≥1.0%","description":"Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.0% at Week 16.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"9.3","spread":null},{"groupId":"OG003","value":"45.9","spread":null},{"groupId":"OG004","value":"19.0","spread":null},{"groupId":"OG005","value":"46.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Decrease in HbA1c ≥1.5%","description":"Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 1.5% at Week 16.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"23.3","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"22.4","spread":null},{"groupId":"OG004","value":"7.9","spread":null},{"groupId":"OG005","value":"8.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Decrease in HbA1c ≥2.0%","description":"Clinical response was assessed by the percentage of participants with a decrease from Baseline in HbA1c of greater than or equal to 2.0% at Week 16.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"8.9","spread":null},{"groupId":"OG002","value":"0.0","spread":null},{"groupId":"OG003","value":"9.2","spread":null},{"groupId":"OG004","value":"1.6","spread":null},{"groupId":"OG005","value":"3.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":92},"commonTop":["Hyperlipidaemia","Upper respiratory tract infection","Urinary tract infection","Blood triglycerides increased"]}}}